scholarly journals Serum CXCL9 as a potential marker of Type 1 inflammation in the context of eosinophilic asthma

Allergy ◽  
2019 ◽  
Vol 74 (12) ◽  
pp. 2515-2518
Author(s):  
Takehiro Hasegawa ◽  
Takahiro Okazawa ◽  
Hitoshi Uga ◽  
Hirokazu Kurata ◽  
Akio Mori
Keyword(s):  
Eosinophilic Asthma ◽  
Potential Marker

scholarly journals Increased UBE2L6 regulated by type 1 interferon as potential marker in TB

2021 ◽  
Author(s):  
Jiao Gao ◽  
Chonghui Li ◽  
Wenjing Li ◽  
Haotian Chen ◽  
Yurong Fu ◽  
...  
Keyword(s):  
Type 1 Interferon ◽  
Potential Marker

Biomarkers of bone metabolism in horses: Ante-mortem versus post-mortem correlation in serum and aqueous humour

2002 ◽  
Vol 15 (02) ◽  
pp. 67-71
Author(s):  
L. T. Glickman ◽  
N. W. Glickman ◽  
E. S. Rasmussen ◽  
S. J. Carlson ◽  
G. J. Breur ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Metabolism ◽  
Aqueous Humour ◽  
Bone Alkaline Phosphatase ◽  
Serum Marker ◽  
Post Mortem ◽  
Potential Marker ◽  
Serum Ictp

SummaryThe objective of this study was to determine the correlation between ante-mortem and 24-hour postmortem concentrations of four markers of bone metabolism in equine serum and aqueous humour. The markers evaluated were osteocalcin, bone alkaline phosphatase, carboxyterminal propeptide of type-1 procollagen and carboxyterminal cross-linked telopeptide of type-1 collagen (ICTP). The concentrations of these markers were poorly correlated (P > 0.05) between aqueous humour and serum. ICTP was the only serum marker significantly correlated (r = 0.93) between ante- and post-mortem samples. ICTP is, therefore, a potential marker for evaluating antemortem markers of bone metabolism in dead horses.

scholarly journals Galectin-3 as a potential marker of myocardial hypertrophy in essential hypertension in individuals with polymorphic AT1R genotypes

2018 ◽  
Vol 5 (8) ◽  
pp. 2633-2644
Author(s):  
Ruzhanskaya V.O. ◽  
Sivak V.G. ◽  
Sakovych O.O. ◽  
Pashkova J.P. ◽  
Zhebel V.M.
Keyword(s):  
Essential Hypertension ◽  
Myocardial Hypertrophy ◽  
Receptor Gene ◽  
Laboratory Findings ◽  
Potential Marker ◽  
Clinical Center ◽  
Galectin 3 ◽  
Polymorphic Variants ◽  
Biochemical Analyses

Background: The potential use of plasma galectin-3 level as a of myocardial changes in the development of hypertrophy in males with essential hypertension (EH), carriers of polymorphic variants of II type 1 receptor gene, was studied. The level of brain peptide (BNP), as well as the parameters of central and systemic, and structural and functional parameters of the heart in carriers of polymorphic variants of II type 1 receptor gene, were studied as reference. Methods: The study included 79 individuals with no signs of cardiovascular disease, and 62 males with stage II EH, aged 40-60, who were residents of Ukraine. All patients were treated at the Military Medical Clinical Center of Central Region of Air Forces of Ukraine and Vinnytsia Regional Specialized Clinical Hospital of Radiation Protection of the Ministry of Health of Ukraine, from December 2013 to June 2015. The patients were studied during their treatment at the in-patient department. Anesthetic, clinical and laboratory findings, and measures were entered into a special chart. Biochemical analyses were done upon admission of the patients to the hospital. Immunologic, and instrumental methods of examination were used as well. Statistical analyses of the results obtained were done on a personal computer using standard statistical package STATISTICA 10. Microsoft Excel was used for primary preparations of tables and intermediate calculations. Results: In patients with EH and myocardial hypertrophy, the C allele of angiotensin II type 1 receptor gene was found to be dominating. They had higher levels of both galectin-3 and BNP. The threshold levels of galectin-3 and BNP for screening diagnosis of EH with myocardial hypertrophy in males (who were residents of the Podillya region of Ukraine) were evaluated.

scholarly journals Levels of Urinary Trypsin Inhibitor and Structure of Its Chondroitin Sulphate Moiety in Type 1 and Type 2 Diabetes

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Antonio Junior Lepedda ◽  
Gabriele Nieddu ◽  
Silvia Rocchiccioli ◽  
Nadia Ucciferri ◽  
Michela Idini ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Trypsin Inhibitor ◽  
Chondroitin Sulphate ◽  
Albumin Excretion Rate ◽  
Anion Exchange Chromatography ◽  
Exchange Chromatography ◽  
Urinary Trypsin Inhibitor ◽  
Potential Marker

Background. Diabetes mellitus is a global health problem representing the fifth leading cause of mortality and a major risk factor for cardiovascular diseases. In the last years, we reported an association among urinary trypsin inhibitor (UTI), a small proteoglycan that plays pleiotropic roles in many inflammatory processes, and both type 1 and 2 diabetes and developed a method for its direct quantitation and structural characterization. Methods. Urine from 39 patients affected by type 1 diabetes, 32 patients with type 2 diabetes, and 52 controls were analysed. UTI was separated from the main glycosaminoglycans physiologically present in urine by anion exchange chromatography, treated for chondroitin sulphate (CS) chain complete depolymerisation, and analysed for both UTI content and CS structure. UTI identification was performed by nano-LC-MS/MS analysis. Results. We evidenced increased UTI levels, as well as reduced sulphation of its CS moiety in association with diabetes, regardless of both age and medium-term glycaemic control. Furthermore, no association between UTI and albumin excretion rate was found. Conclusions. Evidences suggest that UTI levels are not directly correlated with renal function or, otherwise, that they may increase before the onset of renal impairment in diabetes, representing a potential marker for the underlying inflammatory condition.

Sign in / Sign up

Export Citation Format

Share Document